Analyst upgrades:

• Keefe Bruyette upgraded Blackstone Group (BX) to outperform from market perform following the company's Q3 results and maintains an $18.50 price target on shares.
• Baird upgraded Astec (ASTE) to outperform from neutral citing relative valuation and upside from new multi-year U.S. highway funding legislation. The firm raised its target to $33 from $27.
• Goldman upgraded Abercrombie & Fitch (ANF) to conviction buy from neutral citing "significant" long-term growth drivers that include international growth. The firm raised its target to $45 from $36.
• Ariad Pharmaceuticals (ARIA) was upgraded to overweight from neutral at JPMorgan.
• Energizer (ENR) was upgraded to overweight from equal weight at Morgan Stanley.
• AstraZeneca (AZN) was upgraded to buy from hold at RBS.

Analyst upgrades:

• Deutsche Bank upgraded Cemex (NYSE: CX) to Buy from Hold on decreased dilution risk following the company's successful refinancing and raised its target on shares to $15 from $11.20.
• Rochdale upgraded Wal-Mart (NYSE: WMT) to Buy from Neutral and raised its target to $65. The firm is positive on Wal-Mart's defensive characteristics, cyclical upside, and competitive position.
• JPMorgan upgraded Gartner Group (NYSE: IT) to Overweight from Neutral to reflect stabilization in IT industry spending and the stock's attractive valuation. The firm has a $23 price target on the stock.
• Cavium Networks (NASDAQ: CAVM) was upgraded to Overweight from Equal Weight at Barclays.
• Borg-Warner (NYSE: BWA) was upgraded to Buy from Neutral at BofA/Merrill.
• Nanometrics (NASDAQ: NANO) was upgraded to Outperform from Perform at Oppenheimer.

MOST NOTEWORTHY: Ariad Pharma, FNB Corp. and Fortune Brands were today's noteworthy initiations:

• Jefferies finds Ariad Pharma (NASDAQ:ARIA) compelling as they believe the market potential for deforolimus in cancer is being underappreciated. Jeffieries initiated Ariad with a Buy rating and $8 target.
  
• B. Riley assumed coverage of FNB Corp. NYSE:FNB) with a Neutral rating and $15 target and sees limited viable lending opportunities in the current economic environment.
  
• Wachovia initiated Fortune Brands (NYSE:FO) with an Outperform rating and is positive on the company's position in Spirits. The firm believes its Home business is weighted towards the less cyclical remodels business.

OTHER INITIATIONS:

• William Blair initiated Smart Balance (NASDAQ:SMBL) with a Market Perform rating.
  
• Wachovia started PepsiCo (NYSE:PEP) and Anheuser-Busch (NYSE:BUD) with Market Perform ratings.

MAJOR PAPERS:

• Amid mounting criticism for its role in the subprime crisis, McGraw Hill Companies Inc (NYSE: MHP) replaced Kathleen Corbet, the president of Standard & Poors, with Deven Sharma, a McGraw Hill senior VP who has been with S&P since the end of last year, reported the Wall Street Journal.
• Barron's Online's "Inside Scoop" column reported that Aeropostale Inc (NYSE: ARO) CFO Michael Cunningham sold $2.1M in stock Monday at an average price of $22.43 per share, according to SEC data.

OTHER PAPERS:

• Indian IT outsourcing companies Infosys Technologies (NASDAQ: INFY) and Wipro Limited (NYSE: WIT) have reportedly both shown interest in buying out the US-based high-end analytics company MarketRx, which is believed to be worth between $150M and $160M, reported the Economic Times.
• The New York Times reported that General Electric Company's (NYSE: GE) NBC Universal has decided not to renew its contract to sell digital downloads of television shows on Apple Inc's (NASDAQ: AAPL) iTunes online store.
• From BusinessWeek's "Inside Wall Street" column:
  
• Coca-Cola Company (NYSE: KO) is making a comeback, thanks to its huge global distribution edge.
  
• Southern Copper Corporation (NYSE: PCU) is a good copper play, as it is undervalued and ignored, especially considering its 6.21% dividend yield.
  
• Ariad Pharmaceuticals (NASDAQ: ARIA) may be one of the more underappreciated and undervalued biotech stocks around.